Rare Dermatology News

Spotlight On

Alopecia totalis (AT)

Alopecia totalis is the loss of all skull and facial hair


30 / 100,000


US Estimated


Europe Estimated

Age of Onset





Autosomal dominant


Autosomal recessive




X-linked dominant


X-linked recessive


5 Facts you should know



A condition characterized by the complete loss of hair on the scalp



An advanced form of alopecia areata



It is thought to be an autoimmune condition in which the immune system mistakenly attacks the hair follicles



Roughly 20% of affected people have a family member with alopecia



Among those in whom all body hair is lost, fewer than 10% recover

Alopecia totalis (AT) is also known as...

Alopecia totalis

Loss of all scalp hair

What’s your Rare IQ?

In what form of hair loss is the entire body affected?

Common signs & symptoms

Alopecia of scalp

Pathologic hair loss from scalp
Scalp hair loss

Current treatments


Your doctor may prescribe a corticosteroid to suppress your immune system. This stops the immune system from attacking healthy tissue. As a result, you may notice less hair loss. You may begin to regrow hair in affected areas.

Topical immunotherapy

This treatment boosts your immune system to help your body fight the condition. If effective, this therapy can stimulate your hair follicles, resulting in new hair growth.

Minoxidil (Rogaine)

This hair growth treatment can be used by children and adults. For best results, use this medication in conjunction with other therapies. Hair may begin to regrow within three months.

Diphencyprone (DPCP)

DPCP is a topical treatment designed to stimulate an allergic reaction, which prompts an increase in white blood cell count. This response helps stimulate hair follicles and promotes hair growth.

Ultraviolet light therapy

This treatment increases blood circulation to hair follicles and stimulates hair growth. If you’re able to regrow your hair, there’s still a risk of losing it again. Hair loss can recur once treatment ends.


This novel therapy, originally developed for rheumatoid arthritis, shows significant promise in treating the many forms of alopecia areata.

Top Clinical Trials

TitleDescriptionPhasesStatusInterventionsMore Information
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATAThis is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).

Phase 2Active, not recruitingDrug: PF-06651600|Drug: PlaceboMore Info
Long-Term PF-06651600 for the Treatment of Alopecia AreataThis is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.Phase 3Active, not recruitingDrug: PF-06651600|Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccineMore Info

Top Treatments in Research

AgentClass/Mechanism of ActionDevelopment StatusCompanyClinical StudiesMore Information
PF-06651600An irreversible inhibitor of JAK3 with selectivity over the other three JAK isoforms.Phase 2PfizerMore InfoMore Info